文献速递肝病

头孢噻肟、头孢曲松或环丙沙星反应指导治疗自发性细菌性腹膜炎:一项随机试验:2021 AASLD 自发性细菌性腹膜炎实践指南的验证研究

Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Randomized Trial: A Validation Study of 2021 AASLD Practice Guidance for SBP.
PubMed 文献 · Am J Gastroenterol · 2023-01-03

这项多中心前瞻性随机对照试验纳入261例肝硬化腹水合并自发性细菌性腹膜炎患者,比较头孢噻肟、头孢曲松和环丙沙星在反应指导治疗下的疗效。120小时缓解率分别为67.8%、77.0%和73.6%(P=0.388),1个月死亡率组间相似(P=0.770)。结论认为三种经验性抗生素疗效无显著差异,基于反应指导治疗仍可作为初始治疗,尤其在社区获得性感染中。

要点

  • 120小时缓解率头孢噻肟组67.8%、头孢曲松组77.0%、环丙沙星组73.6%(P=0.388)。
  • 1个月死亡率三组相似(P=0.770)。
  • MELD评分和SBP缓解是生存的显著影响因素。

核心结论

  • 头孢噻肟、头孢曲松和环丙沙星等经验性抗生素对SBP的疗效无显著差异。
  • 基于反应指导治疗的这些抗生素仍可作为SBP初始治疗有效,尤其在社区获得性感染中。

研究设计与样本

  • 多中心、前瞻性、随机对照试验。
  • 纳入16至75岁肝硬化腹水、多形核细胞计数>250/mm³的患者。
  • 共纳入261例发生SBP的肝硬化患者。
  • 48小时行随访腹腔穿刺决定继续或更换指定抗生素,评估治疗120和168小时缓解率。

主要发现

  • 120小时缓解率(主要终点)在意向性治疗分析中头孢噻肟组67.8%、头孢曲松组77.0%、环丙沙星组73.6%(P=0.388)。
  • 1个月死亡率组间相似(P=0.770)。
  • MELD评分和SBP缓解是生存的显著影响因素。
  • 多数患者在入院48小时内诊断为SBP。

关键数值与推荐

  • SBP纳入标准为肝硬化腹水且多形核细胞计数>250/mm³。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: For the treatment of spontaneous bacterial peritonitis (SBP), cefotaxime, ceftriaxone, and ciprofloxacin were used as first-line agents. However, considering the increasing rate of antibiotic resistance, it is unclear which of these drugs can be initially recommended. This study aimed to compare the current efficacy of the 3 antibiotics, namely cefotaxime, ceftriaxone, and ciprofloxacin, for the treatment of SBP in patients with cirrhosis with ascites, when guided by therapeutic responses. METHODS: This study was a multicenter, prospective, randomized controlled trial. The inclusion criteria were 16- to 75-year-old patients with liver cirrhosis with ascites, having polymorphonuclear cell count of >250/mm 3 . We performed a follow-up paracentesis at 48 hours to decide continuing or changing the assigned antibiotics and then assessed the resolution rates at 120 and 168 hours of treatment. RESULTS: A total of 261 patients with cirrhosis who developed SBP were enrolled. Most of the patients were diagnosed as those with SBP within 48 hours of admission. The resolution rates at 120 hours, which is the primary endpoint, were 67.8%, 77.0%, and 73.6% in the cefotaxime, ceftriaxone, and ciprofloxacin groups, respectively ( P = 0.388), by intension-to-treat analysis. The 1-month mortality was similar among the groups ( P = 0.770). The model for end-stage liver disease score and the SBP resolution were significant factors for survival. CONCLUSION: The efficacy of empirical antibiotics, such as cefotaxime, ceftriaxone, and ciprofloxacin, against SBP was not significantly different. In addition, these antibiotics administered based on response-guided therapy were still efficacious as initial treatment for SBP, especially in those with community-acquired infections.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Yim HJ, Kim TH, Suh SJ, et al. Response-Guided Therapy With Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Randomized Trial: A Validation Study of 2021 AASLD Practice Guidance for SBP. Am J Gastroenterol. 2023. PMID: 36594820. doi:10.14309/ajg.0000000000002126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。